Published in Clin Cancer Res on January 01, 2005
Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer (2010) 3.84
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther (2009) 2.50
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell (2007) 2.05
Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res (2008) 1.40
Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer (2009) 1.32
Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther (2012) 1.26
The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia (2012) 1.25
miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One (2012) 1.20
miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene (2011) 1.20
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res (2010) 1.18
Microtubules and their role in cellular stress in cancer. Front Oncol (2014) 1.15
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res (2010) 1.14
Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics (2008) 1.13
A transgenic mouse class-III beta tubulin reporter using yellow fluorescent protein. Genesis (2007) 1.11
The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers. Br J Cancer (2008) 1.10
Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol (2009) 1.06
miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. PLoS One (2014) 1.05
Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance. J Med Chem (2010) 1.02
Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. Cancer Res (2011) 1.01
Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer (2006) 1.00
Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. PLoS One (2012) 0.99
Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res (2012) 0.98
The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inform (2007) 0.98
Enzyme-instructed self-assembly: a multistep process for potential cancer therapy. Bioconjug Chem (2015) 0.97
Isolation of glioma cancer stem cells in relation to histological grades in glioma specimens. Childs Nerv Syst (2012) 0.94
TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer (2008) 0.94
Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani. Br J Clin Pharmacol (2010) 0.93
Identification and characterization of renal cell carcinoma gene markers. Cancer Inform (2007) 0.92
A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor. Asian J Androl (2011) 0.91
Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer (2011) 0.91
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer (2014) 0.91
βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget (2015) 0.90
RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. Br J Cancer (2012) 0.89
Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clin Exp Metastasis (2013) 0.88
Expressions of Thymidylate Synthase,Thymidine Phosphorylase, Class III β-tubulin, and Excision Repair Cross-complementing Group 1predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin. Chin J Cancer Res (2011) 0.88
Conformational analysis of the carboxy-terminal tails of human beta-tubulin isotypes. Biophys J (2007) 0.88
Mechanisms of resistance to cabazitaxel. Mol Cancer Ther (2014) 0.87
The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: a retrospective clinical study. J Cancer Res Clin Oncol (2009) 0.86
P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer (2009) 0.86
Clinical trial designs for testing biomarker-based personalized therapies. Clin Trials (2012) 0.86
Synthesis and Biological Evaluation of Novel 3'-Difluorovinyl Taxoids. J Fluor Chem (2012) 0.86
Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells. PLoS One (2014) 0.85
Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells. Breast Cancer Res (2012) 0.85
Determination of the optimal tubulin isotype target as a method for the development of individualized cancer chemotherapy. Theor Biol Med Model (2013) 0.84
Novel water-soluble substituted pyrrolo[3,2-d]pyrimidines: design, synthesis, and biological evaluation as antitubulin antitumor agents. Pharm Res (2012) 0.83
Isolation of tumor spheres and mesenchymal stem-like cells from a single primitive neuroectodermal tumor specimen. Childs Nerv Syst (2013) 0.83
Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane. Exp Ther Med (2010) 0.82
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed Res Int (2015) 0.82
Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol (2015) 0.81
Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer. Int J Pharm (2014) 0.81
Synthesis and biological activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents. J Med Chem (2011) 0.81
The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer. Int J Mol Sci (2015) 0.81
MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers. J Cell Mol Med (2013) 0.81
The somatostatin 2A receptor is enriched in migrating neurons during rat and human brain development and stimulates migration and axonal outgrowth. PLoS One (2009) 0.81
A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy. BMC Med Genomics (2012) 0.81
Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel. J Ovarian Res (2012) 0.81
The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorg Med Chem (2014) 0.80
Nanoparticle-mediated drug delivery for treating melanoma. Nanomedicine (Lond) (2015) 0.79
Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells. BMC Cancer (2010) 0.79
MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88. J Ovarian Res (2015) 0.79
MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression. Oncotarget (2016) 0.79
Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer. BMC Cancer (2015) 0.78
Carboxymethylcellulose-based and docetaxel-loaded nanoparticles circumvent P-glycoprotein-mediated multidrug resistance. Mol Pharm (2014) 0.78
Rationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis. BMC Res Notes (2012) 0.78
An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells. PLoS One (2013) 0.77
βIII-Tubulin Regulates Breast Cancer Metastases to the Brain. Mol Cancer Ther (2015) 0.77
Molecular insight of isotypes specific β-tubulin interaction of tubulin heterodimer with noscapinoids. J Comput Aided Mol Des (2014) 0.77
The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. Curr Genomics (2008) 0.77
Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment. Am J Cancer Res (2016) 0.76
Synthesis and Cytotoxicity Evaluation of C4- and C5-Modified Analogues of the α,β-Unsaturated Lactone of Pironetin. ChemMedChem (2017) 0.75
Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer. Am J Cancer Res (2015) 0.75
Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins. PLoS One (2016) 0.75
2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance. Bioorg Med Chem (2011) 0.75
Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression. Lung Cancer (2015) 0.75
Taxane anticancer agents: a patent perspective. Expert Opin Ther Pat (2015) 0.75
An In silico Based Comparison of Drug Interactions in Wild and Mutant Human β-tubulin through Docking Studies. Avicenna J Med Biotechnol (2014) 0.75
6-Methoxy Podophyllotoxin Induces Apoptosis via Inhibition of TUBB3 and TOPIIA Gene Expressions in 5637 and K562 Cancer Cell Lines. Cell J (2015) 0.75
Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review. Onco Targets Ther (2015) 0.75
A good molecular target for prostate cancer chemotherapy. Asian J Androl (2011) 0.75
Targeting mitotic pathways for endocrine-related cancer therapeutics. Endocr Relat Cancer (2017) 0.75
[Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)]. Wien Med Wochenschr (2007) 0.75
An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance. Int J Mol Sci (2017) 0.75
Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death. Oncol Lett (2017) 0.75
β3-tubulin is a good predictor of sensitivity to taxane-based neoadjuvant chemotherapy in primary breast cancer. Clin Exp Med (2015) 0.75
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst (2005) 3.64
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol (2008) 2.82
Synthesis of some pyrazole derivatives and preliminary investigation of their affinity binding to P-glycoprotein. Bioorg Med Chem Lett (2005) 2.80
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol (2009) 2.80
Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol (2008) 2.56
Concern Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A (2003) 2.52
Postoperative pain after conventional laparoscopy and laparoendoscopic single site surgery (LESS) for benign adnexal disease: a randomized trial. Fertil Steril (2011) 2.04
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer (2010) 2.03
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol (2004) 1.95
Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecol Oncol (2011) 1.71
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology (2007) 1.70
Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res (2006) 1.67
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood (2006) 1.60
Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood (2002) 1.57
Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res (2011) 1.53
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol (2005) 1.52
Mannose-binding lectin polymorphisms and pulmonary outcome in premature neonates: a pilot study. Intensive Care Med (2007) 1.50
Risk of postoperative pelvic abscess in major gynecologic oncology surgery: one-year single-institution experience. Ann Surg Oncol (2010) 1.50
A prospective study of laparoscopy versus minilaparotomy in the treatment of uterine myomas. J Minim Invasive Gynecol (2005) 1.48
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur J Cancer (2013) 1.48
Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene (2004) 1.46
Minilaparotomy in early stage endometrial cancer: an alternative to standard and laparoscopic treatment. Gynecol Oncol (2002) 1.45
Ischemic injury activates PTHrP and PTH1R expression in human ventricular cardiomyocytes. Basic Res Cardiol (2009) 1.45
Laparoendoscopic single-site surgery (LESS) for ovarian cyst enucleation: report of first 3 cases. Fertil Steril (2009) 1.44
Functional properties of cells obtained from human cord blood CD34+ stem cells and mouse cardiac myocytes in coculture. Am J Physiol Heart Circ Physiol (2008) 1.42
Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample. Biol Proced Online (2001) 1.40
Incidence and risk factors for clinical failure of uterine leiomyoma embolization. Obstet Gynecol (2012) 1.39
Some criticism about postoperative pain after adnexal surgery performed by single-port versus standard laparoscopy. Fertil Steril (2012) 1.39
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 1.36
Myoendothelial differentiation of human umbilical cord blood-derived stem cells in ischemic limb tissues. Circ Res (2003) 1.32
Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology (2004) 1.30
Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene (2007) 1.29
Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol (2004) 1.29
Targeting CD133 antigen in cancer. Expert Opin Ther Targets (2009) 1.26
Syphilis Infection during pregnancy: fetal risks and clinical management. Infect Dis Obstet Gynecol (2012) 1.25
CD133 antigen expression in ovarian cancer. BMC Cancer (2009) 1.23
Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology (2007) 1.22
The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res (2005) 1.20
Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro. Eur J Neurosci (2002) 1.20
Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol (2003) 1.20
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol (2006) 1.19
BRCA1-related malignancies in a family presenting with von Recklinghausen's disease. Gynecol Oncol (2002) 1.19
MiR-200c and HuR in ovarian cancer. BMC Cancer (2013) 1.18
Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res (2009) 1.17
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol (2012) 1.15
Laparoendoscopic single-site surgery for the treatment of benign adnexal disease: a prospective trial. Diagn Ther Endosc (2010) 1.14
Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res (2009) 1.13
Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: the BEST study. Med Care (2012) 1.12
Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol (2008) 1.12
Molecular mechanisms of patupilone resistance. Cancer Res (2008) 1.11
Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. Surg Endosc (2014) 1.10
Pseudo-Meigs' syndrome associated with malignant struma ovarii: a case report. Gynecol Oncol (2004) 1.10
Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression. Apoptosis (2008) 1.10
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer (2011) 1.09
Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res (2004) 1.08
Non-surgical management of uterine fibroids. Hum Reprod Update (2008) 1.08
Comments to “a rational, non-radioactive strategy for the molecular diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency”. Gene (2014) 1.07
HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis (2003) 1.07